Lymphocyte Activation Gene - 3
Protein Market Drivers
Several drugs in clinical trials
that target the LAG-3 protein, is expected to be a major factor contributing in
global Lymphocyte
Activation Gene - 3 Protein Market growth over the forecast period. These
drugs are still in the clinical trials in different phases. For instance, in
2017, BMS-986016 (Relatlimab)—developed by Bristol-Myers Squibb—in combination
with Opdivo (nivolumab), effectively aided in treatment of advanced melanoma
that was previously treated with anti-PD-1/PD-L1 therapy. The drug is in phase
II clinical trial and its estimated study completion date is March 16, 2022.
Immune checkpoint receptors such
as lymphocyte activation gene - 3 (LAG-3) protein are found on cell surface of
effector T cells and regulatory T cells (Tregs). T cells are a type of white
blood cells that eliminate unhealthy or foreign cells that enter the immune
system. Function of lymphocyte activation gene - 3 protein is to control T cell
response, activation, and growth. Lymphocyte activation gene - 3 turns off the
immune response when a T cell is activated to eliminate a target cell. This
prevents the T cells from harming healthy cells. Moreover, lymphocyte
activation gene - 3 protein is associated with T cell exhaustion in which the T
cells become desensitized and lose their ability to function.
LAG-3 is closely associated with
regulation of cytotoxic T cells and regulatory T cells, which has attracted
attention of researchers and manufacturers as a therapeutic target against
cancer. In cancers, lymphocyte activation gene - 3 expressing exhausted
cytotoxic t cells and regulatory T cells (Tregs) are found to be gathered at
tumor locations. Recent studies reported that inhibiting LAG-3 functions allows
T cells to regain their cytotoxic function and affect tumor growth. There are
several LAG-3 protein antibodies in the clinical trials, which are expected to
further advance in clinical trials over the forecast period.
* The sample copy includes: Report Summary, Table of
Contents, Segmentation, Competitive Landscape, Report Structure, Methodology.
Request a sample copy
of this report: https://www.coherentmarketinsights.com/insight/request-sample/2027
Moreover, several other drugs
such as MGD013 sponsored by MacroGenics (estimated study completion date -
August 2022) and IMP321 (eftilagimod alpha) by Immutep (estimated study
completion date is August 2019) that are in Phase 1 clinical trials, is
expected to be a major factor contributing in global LAG-3 protein market growth
over the forecast period.
Manufacturers and researchers are
focused on development of novel therapies that aid in treatment of cancer. High
prevalence of cancer is expected to boost growth of the market. According to
National Cancer Institute, around 1,735,350 new cases of cancer are expected to
be diagnosed in the U.S., in 2018. The most common types of cancer are lung
cancer, breast cancer, prostate cancer, melanoma, bladder cancer, and others.
According to Cancer Research UK, 2015, around 54,900 new cases of breast cancer
are registered in the UK, which account for 15% of all new cancer cases, annually.
However, uncertainty of clinical
trials (as drugs may fail to show efficacy even in late phases of clinical
trials) is expected to restrain the lymphocyte activation gene - 3 protein
market growth over the forecast period.
Browse Research
Report: https://www.coherentmarketinsights.com/ongoing-insight/lymphocyte-activation-gene-3-protein-market-2027
Lymphocyte Activation Gene - 3 Protein
Market Regional Insights
North America is expected to
witness significant growth in the LAG -3 protein market over the forecast
period. Robust pipeline of LAG-3 protein antibodies and the increasing demand
for such drugs is expected to facilitate growth of the market, in the U.S. For
instance, Bristol-Myers Squibb has Relatlimab in phase II clinical trials and
Regeneron Pharmaceuticals Inc., in collaboration with Sanofi, has REGN3767 in
phase I clinical trials, 2017.
High prevalence of various types
of cancer in North America, Europe, and Asia Pacific region is expected to be a
major factor contributing growth of the lymphocyte activation gene - 3 protein
market over the forecast period. According to European Union (EU), in 2014,
almost 1/3rd million people died from cancer in the EU-28. Moreover,
manufacturers are focused on conducting clinical trials in these regions to
expand their potential customer base.
Lymphocyte Activation Gene - 3
Protein Market Key Player
Key players operating in the
global lymphocyte activation gene - 3 protein market include, Bristol-Myers
Squibb, Icell Kealex Therapeutics, Incyte Corporation, MacroGenics, Inc.,
GlaxoSmithKline Plc, Crescendo Biologics Ltd, Regeneron Pharmaceuticals Inc., Sutro
Biopharma Inc., Symphogen A/S, and Immutep Ltd.
Buy-Now this research
report: https://www.coherentmarketinsights.com/insight/buy-now/2027
About
Coherent Market Insights:
Coherent Market
Insights is a prominent market research and consulting firm offering
action-ready syndicated research reports, custom market analysis, consulting
services, and competitive analysis through various recommendations related to
emerging market trends, technologies, and potential absolute dollar
opportunity.
Contact
Us:
mailto:sales@coherentmarketinsights.com
U.S.
Office:
Name: Mr. Shah
Coherent
Market Insights 1001 4th Ave,
# 3200
Seattle, WA 98154, U.S.
US : +1-206-701-6702
UK : +44-020-8133-4027
JAPAN
: +050-5539-1737
No comments:
Post a Comment